Shots:

• Hansa to receive $5M upon execution of the agreement and AskBio to get an exclusive option to enter into a full development and commercialization agreement based on the results from an initial P-I/II study
• Under the feasibility program, AskBio will be responsible for conducting the pre-clinical and clinical studies with imlifidase. Hansa will be responsible to supply its materials along with an additional support
• The companies collaborated to evaluate imlifidase as a potential pre-treatment prior to the administration of gene therapy in Pompe disease for patients with NAbs to AAV

Ref: PR Newswire | Image: Hansa Biopharma